News X4 cues up FDA verdict in April for WHIM syndrome drug The FDA has started a priority review of X4 Pharma’s mavorixafor, angling to become the first therapy for the rare disease WHIM syndrome, with a decision due by 30th April
News X4 Pharmaceuticals announces positive top-line results for W... X4 Pharmaceuticals has announced
News FDA finally okays Novavax's COVID-19 jab, with restrictions The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.